micro-community-banner
 
  • Saved

2yr
A Preview of the American Academy of Neurology: AAN 2023 Annual Meeting

The American Academy of Neurology (AAN) is hosting its 75th annual meeting in Boston from April 22 to 27, 2023. Attendees have options for in-person or virtual sessions.

Virtual attendees can explore an online poster gallery and will have access to AAN Rewind to view missed sessions within 48 hours of their conclusion. In-person attendees will receive one complimentary ticket to the 75th Anniversary Celebration on Sunday, April 23, and can attend their choice of eight hands-on skills workshops.

Click above for an exclusive preview of the event. 

  • Saved

2yr
Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis - PubMed

Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37013835/

Treatment of acute exacerbations and refractory myasthenia gravis (MG) remains challenging despite advances in immunotherapy. Frequent use of plasmapheresis and immunoglobulins are associated with adverse events and strain on resources....

Conclusions/Relevance: Efgartigimod is a well-tolerated drug that inhibits IgG autoantibodies with minor side effects such as headache and upper respiratory (lung) and urinary tract infections. Efgartigimod may be a potential treatment strategy in patients with MG. Studies are now being carried out to determine how efgartigimod works in a...

  • Saved

2yr
JPMA - Journal Of Pakistan Medical Association

JPMA - Journal Of Pakistan Medical Association

Source : https://jpma.org.pk/article-details/11643?article_id=11643

Kashaf Waqar ( Fifth Year MBBS Student, CMH Multan Institute of Medical Sciences, Multan, Pakistan. ) Anika Zainab ( Fifth Year MBBS Student, CMH Multan Institute of Medical Sciences, Multan,...

Relevance: Efgartigimod was FDA approved for treating myasthenia gravis on 17th December 2021.

  • Saved

2yr
Case report: Immune remission from generalized myasthenia gravis in a dog with a thymoma and cholangiocellular carcinoma

Case report: Immune remission from generalized myasthenia gravis in a dog with a thymoma and cholangiocellular carcinoma

Source : https://www.frontiersin.org/articles/10.3389/fvets.2023.1124702/full

A 9-year-old male neutered Cockapoo was presented with an acute and progressive history of exercise induced weakness involving all limbs, and bilateral decreased ability to blink. Investigations revealed generalized myasthenia...

Conclusion: This is the first report describing the temporal evolution of serum AChR antibody concentration in a dog with thymoma-associated myasthenia gravis that achieved immune remission following thymectomy. Treatment was successfully discontinued without any clinical deterioration thereafter despite serum acetylcholine receptor antibody...

  • Saved

2yr
Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT) - Journal of Neurology

Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT) - Journal of Neurology

Source : https://link.springer.com/article/10.1007/s00415-022-11517-w

There are substantial disease and health-related quality-of-life (HRQoL) burdens for many patients with myasthenia gravis (MG), especially for those whose disease symptoms are not well controlled. HRQoL measures such as...

Conclusion: Treatment with efgartigimod resulted in significant and rapid HRQoL improvements for up to 8 weeks after the first infusion in TC 1 and TC 2.